Dietary Polysaccharide from Enteromorpha Clathrata Modulates Gut Microbiota and Promotes the Growth of Akkermansia muciniphila, Bifidobacterium spp. and Lactobacillus spp

Mar Drugs. 2018 May 17;16(5):167. doi: 10.3390/md16050167.

Abstract

Recently, accumulating evidence has suggested that Enteromorpha clathrata polysaccharide (ECP) could contribute to the treatment of diseases. However, as a promising candidate for marine drug development, although ECP has been extensively studied, less consideration has been given to exploring its effect on gut microbiota. In this light, given the critical role of gut microbiota in health and disease, we investigated here the effect of ECP on gut microbiota using 16S rRNA high-throughput sequencing. As revealed by bioinformatic analyses, ECP considerably changed the structure of the gut microbiota and significantly promoted the growth of probiotic bacteria in C57BL/6J mice. However, interestingly, ECP exerted different effects on male and female microbiota. In females, ECP increased the abundances of Bifidobacterium spp. and Akkermansia muciniphila, a next-generation probiotic bacterium, whereas in males, ECP increased the population of Lactobacillus spp. Moreover, by shaping a more balanced structure of the microbiota, ECP remarkably reduced the antigen load from the gut in females. Altogether, our study demonstrates for the first time a prebiotic effect of ECP on gut microbiota and forms the basis for the development of ECP as a novel gut microbiota modulator for health promotion and disease management.

Keywords: Akkermansia muciniphila; Bifidobacterium spp.; Enteromorpha clathrata; Lactobacillus spp.; gut microbiota; polysaccharide; prebiotic.

MeSH terms

  • Acute-Phase Proteins / immunology
  • Administration, Oral
  • Animals
  • Aquatic Organisms / metabolism*
  • Bifidobacterium / drug effects
  • Bifidobacterium / isolation & purification
  • Carrier Proteins / blood
  • Carrier Proteins / immunology
  • Computational Biology
  • Dietary Supplements
  • Disease Models, Animal
  • Dysbiosis / blood
  • Dysbiosis / drug therapy*
  • Dysbiosis / immunology
  • Female
  • Gastrointestinal Microbiome / drug effects*
  • Humans
  • Lactobacillus / drug effects
  • Lactobacillus / isolation & purification
  • Male
  • Membrane Glycoproteins / blood
  • Membrane Glycoproteins / immunology
  • Mice
  • Mice, Inbred C57BL
  • Polysaccharides / isolation & purification
  • Polysaccharides / pharmacology*
  • Polysaccharides / therapeutic use
  • Specific Pathogen-Free Organisms
  • Ulva / metabolism*
  • Verrucomicrobia / drug effects
  • Verrucomicrobia / isolation & purification

Substances

  • Acute-Phase Proteins
  • Carrier Proteins
  • Membrane Glycoproteins
  • Polysaccharides
  • lipopolysaccharide-binding protein